Grabar Law Office Investigates Shareholder Claims Against Applied Therapeutics and Others
Philadelphia, Friday, 12 September 2025.
Grabar Law Office is investigating potential shareholder claims involving Applied Therapeutics, following a class action settlement that raises concerns about corporate governance and shareholder rights.
Overview of Investigations
On September 12, 2025, Grabar Law Office announced an investigation into potential claims on behalf of long-term shareholders of several companies, including Applied Therapeutics, Inc. (NASDAQ: APLT), DoubleVerify Holdings, Inc. (NYSE: DV), LuxUrban Hotels Inc. (OTC: LUXH), and Unicycive Therapeutics, Inc. (NASDAQ: UNCY) [1]. This investigation follows a recent class action settlement involving Applied Therapeutics, raising significant concerns among investors regarding corporate governance and shareholder rights [1].
Applied Therapeutics: A Case of Securities Fraud
The investigation into Applied Therapeutics (NASDAQ: APLT) centers around a securities fraud class action that has reached a settlement as of August 25, 2025 [2]. Shareholders allege that the company, through certain of its officers, provided misleading statements about the Phase III INSPIRE trial, particularly concerning electronic data capture issues and dosing errors [2]. These alleged misrepresentations led to artificially inflated share prices, affecting investors who purchased shares prior to January 3, 2024 [2].
DoubleVerify and LuxUrban Hotels Under Scrutiny
Grabar Law Office is also investigating DoubleVerify Holdings, Inc. (NYSE: DV) to determine if certain officers and directors breached fiduciary duties owed to the company. Shareholders who have held DV shares since prior to November 10, 2023, are encouraged to learn more about the investigation [1]. Similarly, LuxUrban Hotels Inc. (OTC: LUXH) faces allegations of making false statements about signed leases and dealing with multiple lawsuits for unpaid rent [1]. Shareholders who acquired LuxUrban shares before November 8, 2023, are advised to seek further information [1].
Unicycive Therapeutics Faces Allegations
The investigation into Unicycive Therapeutics, Inc. (NASDAQ: UNCY) concerns whether certain officers and directors breached their fiduciary duties. Shareholders who purchased shares before March 29, 2024, are eligible to seek corporate reforms and a return of funds to the company [1]. Allegations include overstating readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of the oxylanthanum carbonate new drug application [1].